Monoclonal antibodies and its impact on modern health services- A review

S. Das, V K Sehgal

Abstract


Recent developments in the ability to manipulate immunoglobulin genes has led to development of monoclonal antibodies directed against therapeutic targets. Nowadays, Monoclonal Antibodies act as useful therapies in case of  diseases like Cancer, Autoimmune diseases, Infectious diseases and also in conditions like Transplant rejections. The dream of Monoclonal antibodies has been achieved due to advent of Hybridoma technology in 1975.

Monoclonal antibodies are one of the most upcoming fields in biopharmaceutical sciences. The role they have played has brought a revolution in the sector of health services. Not only as a therapeutic tool, its roleplay has also touched the topics of analysis, purification, enrichment and also in mediation of physiological responses. Today, it is continuing to become a befitting reply to various notorious diseases, for which, health professionals had waited for a long time. The purpose of this manuscript is to bring forward , in brief, the role played by Monoclonal antibodies in health sector, various studies related to this marvellous therpeutic tool and the scope, it carries in the near future, and for many years to come.


Keywords


Monoclonal antibodies, Hybridoma technology, Immunoglobulin, Human mAbs, Cell Engineering

Full Text:

PDF

References


. Anticancer Drugs . Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 7th ed. London: Elsevier; 2012: 634.

. Chemotherapy of Tuberculosis and Leprosy. Sharma HL, Sharma KK. Principles of Pharmacology. 2nd ed. Hyderabad: Paras Medical Publisher; 2013: 753

. Liu JKH. The history of monoclonal antibody development - Progress,

remaining challenges and future innovations. Annals of Medicine and Surgery. 2014; 3: 113-116.

. Pandey S. Hybridoma Technology for production of Monoclonal Antibodies. International Journal of Pharmaceutical Sciences Review and Research. 2010; 1(2): 88-94.

. Chandel P, Harikumar SL. Pharmaceutical Monoclonal Antibodies: Production, guidelines to cell engineering and applications. Int J Pharm Pharm Sci. 2013; 5(2): 13-20.

. Pucca MB, Bertolini TB, Barbosa JE, Galina SVR, Porto GS. Therapeutic monoclonal antibodies: scFv patents as a marker of a new class of potential biopharmaceuticals. Brazilian Journal of Pharmaceutical Sciences. 2011; 47(1): 31-39.

. Siddiqui MZ. Monoclonal Antibodies as Diagnostics; an Appraisal. Indian J. Pharm. Sci. 2010; 72(1): 12-17.

. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of

monoclonal antibodies. Nature reviews/Drug discovery. 2010; 9: 325-38.

. Lipman NS, Jackson LR, Trudel LJ, Garcia FW. Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources. ILAR Journal. 2005; 46(3): 258-68

. McCafferty J, Griffiths A, Winter G, Chiswell D. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348 (6301): 552–54.

. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495–97.

. Ansar W, Ghosh S. Monoclonal Antibodies: A tool in clinical research. Indian Journal of Clinical Medicine. 2013; 4: 9-21.

. Trebak M, Chong JM, Herlyn D, Speicher DW. Effi cient laboratory scale production of monoclonal antibodies using membrane-based high density cell culture technology. J Immunol Methods 1999;230:59-70.

. Leavy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol 2010;10(5):297.

. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone

OKT3: a bibliographic review. Toxicology 1995;105(1):23-9.

. Li F, Vijayasankaran N, Shen AY, Kiss R, Amanullah A. Cell culture processes for

monoclonal antibody production. mAbs 2010;2(5):466-79.

. Chames P, Regenmortel MV, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol .2009;157(2):220-33.

. Houdebine L. Production of pharmaceutical proteins by transgenic animals,

comparative immunology. Microbiol Infect Dis .2009;32(2):107-21.

. Lonberg N. Human monoclonal antibodies from transgenic mice. Ther Antibodies

;181:69-97.

. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumour penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421-34.

. Elements of biotechnology, P.K. GUPTA (1st EDITION): 2006-2007: 203-11.

. http://www.molecular-plant-biotechnology.info/hybridoma-and-monoclonal-antibodies-mabs/ raising-theantibodies.htm

. Holliger P, Prospero T, Winter G. "Diabodies": Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA. 1993; 90: 6444-8.

. Kipriyanov SM. Generation of Bispecific and Tandem Diabodies. Methods in Molecular Biology. 2nd ed. Humana Press. 2009; 562: 179.

. Inbar D, Hochman J, Givol D. Localization of Antibody-Combining Sites within the Variable Portions of Heavy and Light Chains. Proc. Nat. Acad. Sci. USA. 1972; 69(9): 2659-62.

. IgG-Fc interactions in disease. Kanmert D. Structure and Interactions of Human IgG-Fc. Linkoping University; Sweden; 2011: 37.

. Chung, C. H. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008; 13: 725–32.

. Askling, J. et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.Arthritis Rheum. 2005; 52: 1986–92 .

. Theis, VS, Rhodes, JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008; 27: 19–30 .

. Molloy, ES, Calabrese LH. Therapy: targeted but not trouble-free: efalizumab and PML. Nature Rev.Rheumatol. 2009; 5: 418–19 .

. Carson, K. R. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet

Oncol.2009; 10: 816–24 .

. Yousry, T. A. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006; 354: 924–33.

. Topol, E. J. et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am. J. Med. 2002; 113: 1–6 .

. Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary. Nature Rev. Drug Discov. 2009; 7: 909–25.

. Nalluri S R., Chu D., Keresztes R., Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300: 2277–2285 .

. Guan M, Zhou YP, Sun JL, Chen SC. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International. 2014; 2015: 1-13.

. Gressett SM, Shah SR. “Intricacies of bevacizumab -induced toxicities and their management,” Annals of Pharmacotherapy. 2009; 43(3): 490–501.

. Boll´ee G, Patey N, Cazajous G et al. “Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib,” Nephrology Dialysis Transplantation. 2009; 24(2): 682–85.

. Gianni L, Pienkowski T, Im YH et al. “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere ): a randomised multicentre , open-label

phase 2 trial,” The Lancet Oncology. 2012; 13: 25–32.

. Maleki LA, Baradaran B, Majidi J, Mohammadian M, Shahneh MZ. Future prospects of monoclonal antibodies as magic bullets in Immunotherapy. Human antibodies. 2013; 22: 9-13.

. Sood A, Polk D. Amgen Completes Acquisition of Abgenix; Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty [Internet]. [Thousand Oaks, California, USA]: Amgen; 2016. Available from: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=837754

. Regeneron [Internet]. New York: Regeneron Pharmaceuticals inc. Available from https://web.archive.org/web/20090802074131/http://www.regeneron.com:80/about_us.html

. Kymab [Internet]. Cambridge(UK): Kymab ltd. Available from http://www.kymab.com/kymouse_platform.php




DOI: http://dx.doi.org/10.7439/ijpr.v7i8.4296

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 International Journal of Pharmacological Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.